Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$804.25 +0.8%	$764.13	$510.05 ▼ $934.62	$49.37B	0.46	336,748 shs	401,098 shs
INSM Insmed	$107.91 +0.5%	$139.24	$64.85 ▼ $212.75	$23.28B	0.89	3.84 million shs	2.99 million shs
TAK Takeda Pharmaceutical	$16.69 +0.6%	$17.51	$12.99 ▼ $18.90	$52.77B	-0.06	3.01 million shs	1.87 million shs
TEVA Teva Pharmaceutical Industries	$34.32 +0.7%	$31.70	$14.99 ▼ $37.35	$39.17B	0.86	7.46 million shs	6.31 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+0.81%	+0.19%	-3.62%	-5.08%	+39.07%
INSM Insmed	+0.47%	-8.54%	-24.44%	-32.98%	+57.51%
TAK Takeda Pharmaceutical	+0.60%	+0.36%	-5.01%	-10.61%	+17.17%
TEVA Teva Pharmaceutical Industries	+0.57%	-5.36%	+7.11%	-0.11%	+104.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$804.25 +0.8%	$764.13	$510.05 ▼ $934.62	$49.37B	0.46	336,748 shs	401,098 shs
INSM Insmed	$107.91 +0.5%	$139.24	$64.85 ▼ $212.75	$23.28B	0.89	3.84 million shs	2.99 million shs
TAK Takeda Pharmaceutical	$16.69 +0.6%	$17.51	$12.99 ▼ $18.90	$52.77B	-0.06	3.01 million shs	1.87 million shs
TEVA Teva Pharmaceutical Industries	$34.32 +0.7%	$31.70	$14.99 ▼ $37.35	$39.17B	0.86	7.46 million shs	6.31 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+0.81%	+0.19%	-3.62%	-5.08%	+39.07%
INSM Insmed	+0.47%	-8.54%	-24.44%	-32.98%	+57.51%
TAK Takeda Pharmaceutical	+0.60%	+0.36%	-5.01%	-10.61%	+17.17%
TEVA Teva Pharmaceutical Industries	+0.57%	-5.36%	+7.11%	-0.11%	+104.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.92	Moderate Buy	$1,017.78	26.55% Upside
INSM Insmed	2.96	Moderate Buy	$210.95	95.49% Upside
TAK Takeda Pharmaceutical	2.50	Moderate Buy	N/A	N/A
TEVA Teva Pharmaceutical Industries	2.80	Moderate Buy	$41.78	21.75% Upside

Current Analyst Ratings Breakdown

Latest INSM, TAK, ARGX, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2026	INSM Insmed	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$205.00 ➝ $185.00
5/8/2026	INSM Insmed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/8/2026	INSM Insmed	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$230.00 ➝ $226.00
5/8/2026	ARGX argenex	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,120.00 ➝ $1,135.00
5/8/2026	ARGX argenex	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,247.00 ➝ $1,260.00
5/8/2026	INSM Insmed	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$220.00 ➝ $205.00
5/8/2026	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$177.00 ➝ $160.00
5/6/2026	TEVA Teva Pharmaceutical Industries	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$38.00 ➝ $40.00
4/30/2026	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$35.00 ➝ $40.00
4/30/2026	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$36.00 ➝ $42.00
4/30/2026	TEVA Teva Pharmaceutical Industries	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$41.00 ➝ $42.00

(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	11.72	$21.50 per share	37.40	$118.34 per share	6.80
INSM Insmed	$606.42M	38.57	N/A	N/A	$3.25 per share	33.20
TAK Takeda Pharmaceutical	$28.32B	1.87	$3.12 per share	5.34	$16.12 per share	1.04
TEVA Teva Pharmaceutical Industries	$17.26B	2.29	$3.76 per share	9.13	$7.16 per share	4.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$22.46	35.81	24.72	1.26	31.31%	33.28%	28.16%	7/23/2026 (Estimated)
INSM Insmed	-$1.28B	-$5.75	N/A	126.95	N/A	-144.44%	-130.11%	-51.57%	8/6/2026 (Estimated)
TAK Takeda Pharmaceutical	$1.27B	$0.39	42.78	9.48	N/A	4.31%	11.07%	5.49%	7/30/2026 (Estimated)
TEVA Teva Pharmaceutical Industries	$1.41B	$1.33	25.80	11.29	3.29	9.01%	43.53%	8.19%	7/29/2026 (Estimated)

Latest INSM, TAK, ARGX, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	ARGX argenex	$5.74	$5.52	-$0.22	$5.52	$1.44 billion	$1.31 billion
5/7/2026	Q1 2026	INSM Insmed	-$0.90	-$0.76	+$0.14	-$0.76	$300.81 million	$305.96 million
4/29/2026	Q1 2026	TEVA Teva Pharmaceutical Industries	$0.50	$0.53	+$0.03	$0.31	$3.79 billion	$3.98 billion
3/31/2026	Q1 2026	ARGX argenex	N/A	$5.52	N/A	$5.52	N/A	$1.31 billion
3/31/2026	Q4 2025	TAK Takeda Pharmaceutical	N/A	$0.5610	N/A	-$0.0485	N/A	$6.90 billion
3/31/2026	Q1 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.53	N/A	$0.31	N/A	$3.98 billion
2/26/2026	Q4 2025	ARGX argenex	$6.05	$8.02	+$1.97	$8.02	$1.30 billion	$1.32 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.50	3.00%	-18.61%	128.21%	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.23	4.87
INSM Insmed	0.80	4.47	4.10
TAK Takeda Pharmaceutical	0.56	1.27	0.70
TEVA Teva Pharmaceutical Industries	1.70	1.01	0.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
INSM Insmed	N/A
TAK Takeda Pharmaceutical	9.17%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
INSM Insmed	2.10%
TAK Takeda Pharmaceutical	0.04%
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	61.88 million	60.38 million	Optionable
INSM Insmed	1,664	216.75 million	212.20 million	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.15 billion	1.14 billion	Optionable

INSM, TAK, ARGX, and TEVA Headlines

Recent News About These Companies

IFP Advisors Inc Acquires 137,580 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

1 hour ago | marketbeat.com

Teva TD Findings Highlight Underdiagnosis And Shape Neuroscience Growth Story

May 20 at 11:21 AM | finance.yahoo.com

Teva Pharmaceutical Industries (NYSE:TEVA) EVP Sells $5,457,268.11 in Stock

May 20 at 5:35 AM | insidertrades.com

Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Gabelli Funds LLC

May 20 at 3:36 AM | marketbeat.com

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

May 19 at 12:37 PM | finance.yahoo.com

Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?

May 19 at 12:37 PM | finance.yahoo.com

Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?

May 19 at 12:26 PM | zacks.com

Eliyahu Sharon Kalif Sells 153,251 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

May 19 at 4:01 AM | americanbankingnews.com

Teva Pharmaceutical Industries Ltd: Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite ...

May 18 at 9:58 AM | finanznachrichten.de

Teva Pharmaceutical Industries Ltd: Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

May 18 at 9:58 AM | finanznachrichten.de

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

May 18 at 9:58 AM | finance.yahoo.com

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

May 18 at 9:58 AM | finance.yahoo.com

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

May 18 at 8:51 AM | financialpost.comF

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

May 18 at 8:30 AM | globenewswire.com

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

May 18 at 8:00 AM | globenewswire.com

Teva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx Deal

May 16, 2026 | finance.yahoo.com

Teva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by Bessemer Group Inc.

May 16, 2026 | marketbeat.com

Phoenix Financial Ltd. Sells 208,113 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

May 15, 2026 | marketbeat.com

Swiss Life Asset Management Ltd Lowers Position in Teva Pharmaceutical Industries Ltd. $TEVA

May 15, 2026 | marketbeat.com

Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by AustralianSuper Pty Ltd

May 15, 2026 | marketbeat.com

Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More.

May 15, 2026 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INSM, TAK, ARGX, and TEVA Company Descriptions

argenex NASDAQ:ARGX

$804.25 +6.48 (+0.81%)

Closing price 05/20/2026 04:00 PM Eastern

Extended Trading

$804.25 0.00 (0.00%)

As of 04:38 AM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Insmed NASDAQ:INSM

$107.91 +0.50 (+0.47%)

Closing price 05/20/2026 04:00 PM Eastern

Extended Trading

$108.30 +0.39 (+0.36%)

As of 07:18 AM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Takeda Pharmaceutical NYSE:TAK

$16.68 +0.11 (+0.63%)

Closing price 05/20/2026 03:59 PM Eastern

Extended Trading

$16.46 -0.22 (-1.35%)

As of 07:18 AM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Teva Pharmaceutical Industries NYSE:TEVA

$34.32 +0.25 (+0.72%)

Closing price 05/20/2026 03:59 PM Eastern

Extended Trading

$34.21 -0.11 (-0.32%)

As of 07:31 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INSM, TAK, ARGX, and TEVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INSM, TAK, ARGX, and TEVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INSM, TAK, ARGX, and TEVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INSM, TAK, ARGX, and TEVA Company Descriptions

argenex NASDAQ:ARGX

Insmed NASDAQ:INSM

Takeda Pharmaceutical NYSE:TAK

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INSM, TAK, ARGX, and TEVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INSM, TAK, ARGX, and TEVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INSM, TAK, ARGX, and TEVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INSM, TAK, ARGX, and TEVA Company Descriptions

argenex NASDAQ:ARGX

Insmed NASDAQ:INSM

Takeda Pharmaceutical NYSE:TAK

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools